Baseline characteristics
| . | Placebo . | CLA . | t10c12 CLA . |
|---|---|---|---|
| n | 19 | 19 | 19 |
| Age (years) | 53 ± 10.1 | 51 ± 7.1 | 55 ± 7.1 |
| Heredity for diabetes (%) | 8.8 | 10.5 | 7.0 |
| Antihypertensive therapy (%) | 9.0 | 7.2 | 6.1 |
| Weight (kg) | 97.8 ± 10.0 | 98.3 ± 10.1 | 100.2 ± 12.0 |
| BMI (kg/m2) | 30.2 ± 1.8 | 30.1 ± 1.8 | 31.2 ± 2.5 |
| Waist-to-hip ratio | 1.01 ± 0.03 | 1.01 ± 0.02 | 1.01 ± 0.03 |
| Waist girth (cm) | 112.2 ± 5.0 | 112.5 ± 7.1 | 116.0 ± 9.6 |
| SAD (cm) | 28.2 ± 1.8 | 28.2 ± 1.9 | 28.9 ± 2.3 |
| Body fat (%) | 35.3 ± 4.6 | 36.4 ± 4.4 | 36.7 ± 3.0 |
| Lean body mass (kg) | 61.9 ± 6.9 | 61.1 ± 6.0 | 61.9 ± 7.3 |
| Insulin sensitivity (M) (mg · kg−1 · min) | 3.7 ± 1.6* | 4.5 ± 1.5 | 3.9 ± 1.5 |
| Plasma insulin (pmol/l) | 73.2 ± 30 | 64.8 ± 23.4 | 68.4 ± 26.4 |
| Plasma glucose (mmol/l) | 5.7 ± 0.6 | 5.9 ± 0.7 | 5.6 ± 0.6 |
| HbAlc (%) | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.3 |
| Serum cholesterol (mmol/l) | 5.8 ± 1.2 | 5.5 ± 0.8 | 6.0 ± 1.3 |
| LDL cholesterol (mmol/l) | 4.0 ± 0.9 | 3.8 ± 0.7 | 4.0 ± 1.1 |
| HDL cholesterol (mmol/l) | 1.0 ± 0.1 | 1.0 ± 0.2 | 1.0 ± 0.1 |
| VLDL triglycerides (mmol/l) | 1.5 ± 0.9 | 1.2 ± 0.4 | 1.9 ± 2.1 |
| Serum TG (mmol/l) | 2.0 ± 1.0 | 1.7 ± 0.5 | 2.4 ± 2.2 |
| Serum FFAs (mmol/l) | 0.56 ± 0.16 | 0.55 ± 0.18 | 0.61 ± 0.18 |
| Serum free glycerol (mmol/l) | 0.120 ± 0.02 | 0.122 ± 0.02 | 0.131 ± 0.03 |
| Serum leptin (ng/ml) | 10.4 ± 4.6 | 13.2 ± 10.2 | 11.6 ± 5.6 |
| . | Placebo . | CLA . | t10c12 CLA . |
|---|---|---|---|
| n | 19 | 19 | 19 |
| Age (years) | 53 ± 10.1 | 51 ± 7.1 | 55 ± 7.1 |
| Heredity for diabetes (%) | 8.8 | 10.5 | 7.0 |
| Antihypertensive therapy (%) | 9.0 | 7.2 | 6.1 |
| Weight (kg) | 97.8 ± 10.0 | 98.3 ± 10.1 | 100.2 ± 12.0 |
| BMI (kg/m2) | 30.2 ± 1.8 | 30.1 ± 1.8 | 31.2 ± 2.5 |
| Waist-to-hip ratio | 1.01 ± 0.03 | 1.01 ± 0.02 | 1.01 ± 0.03 |
| Waist girth (cm) | 112.2 ± 5.0 | 112.5 ± 7.1 | 116.0 ± 9.6 |
| SAD (cm) | 28.2 ± 1.8 | 28.2 ± 1.9 | 28.9 ± 2.3 |
| Body fat (%) | 35.3 ± 4.6 | 36.4 ± 4.4 | 36.7 ± 3.0 |
| Lean body mass (kg) | 61.9 ± 6.9 | 61.1 ± 6.0 | 61.9 ± 7.3 |
| Insulin sensitivity (M) (mg · kg−1 · min) | 3.7 ± 1.6* | 4.5 ± 1.5 | 3.9 ± 1.5 |
| Plasma insulin (pmol/l) | 73.2 ± 30 | 64.8 ± 23.4 | 68.4 ± 26.4 |
| Plasma glucose (mmol/l) | 5.7 ± 0.6 | 5.9 ± 0.7 | 5.6 ± 0.6 |
| HbAlc (%) | 4.4 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.3 |
| Serum cholesterol (mmol/l) | 5.8 ± 1.2 | 5.5 ± 0.8 | 6.0 ± 1.3 |
| LDL cholesterol (mmol/l) | 4.0 ± 0.9 | 3.8 ± 0.7 | 4.0 ± 1.1 |
| HDL cholesterol (mmol/l) | 1.0 ± 0.1 | 1.0 ± 0.2 | 1.0 ± 0.1 |
| VLDL triglycerides (mmol/l) | 1.5 ± 0.9 | 1.2 ± 0.4 | 1.9 ± 2.1 |
| Serum TG (mmol/l) | 2.0 ± 1.0 | 1.7 ± 0.5 | 2.4 ± 2.2 |
| Serum FFAs (mmol/l) | 0.56 ± 0.16 | 0.55 ± 0.18 | 0.61 ± 0.18 |
| Serum free glycerol (mmol/l) | 0.120 ± 0.02 | 0.122 ± 0.02 | 0.131 ± 0.03 |
| Serum leptin (ng/ml) | 10.4 ± 4.6 | 13.2 ± 10.2 | 11.6 ± 5.6 |
Data are means ± SD unless noted otherwise. There were no significant differences between the groups (ANOVA).
n = 18 in the placebo group.